Solana (SOL) rebounds from $75.64 as swing failure pattern forms at key support. BSOL ETF sees $3M inflow while SOL battles $82 resistance zone.
Browsing: News
Bitcoin rebounds above $65,000 on dollar weakness and Asian rally. US futures steady before Nvidia earnings. Experts question if crypto has truly bottomed.
Kraken debuts regulated perpetual futures for tokenized stocks like Apple (AAPL), Nvidia (NVDA), and Tesla (TSLA) with 24/7 trading and up to 20x leverage.
Ethereum (ETH) falls to $1,800 amid bearish options flow, $405M ETF outflows, and Vitalik’s $7.3M sale. Network activity hits multi-year lows.
XRP (XRP) trades at $1.39 with recurring pre-rally signals and $1.23B in ETF inflows. Analysis of key technical levels and price targets ahead.
Stripe is reportedly exploring acquisition talks with PayPal (PYPL). Stock rose 7% on reports. Both firms operate major stablecoin platforms.
IBM stock crashed 28.6% in under a month after Anthropic’s COBOL AI announcement. Jefferies analyst maintains Buy rating with $370 price target, citing strong AI.
Cipher Digital (CIFR) Q4 earnings miss estimates at $60M revenue and -$0.14 EPS, but company secures 600MW data center deals with AWS and Google for HPC pivot.
Constellation Energy (CEG) stock climbs after reporting Q4 EPS of $2.30, beating analyst forecasts. Revenue reaches $6.07B. Dividend boost announced.
Nvidia (NVDA) reports Q4 FY26 earnings Feb 25. Analysts expect $66.1B revenue (+68% YoY). Wall Street consensus: Strong Buy with $265 target. Full preview.
Novo Nordisk (NVO) UBT251 obesity drug shows 19.7% weight loss in China trial. The triple-G drug targets GLP-1, GIP, and glucagon in mid-stage testing.
Citi and Goldman Sachs maintain Buy ratings on Microsoft (MSFT) as Azure surges 39%, Copilot reaches 15M users, and Maia 200 chip closes performance gap.
Intel (INTC) invests in SambaNova’s $350M funding round and forms AI chip partnership after failed $1.6B buyout. SN50 chip targets Nvidia’s B200 GPUs.
Lemonade (LMND) stock tumbles 12% after Q4 earnings as 2026 guidance disappoints. Piper Sandler lowers price target to $65. Analysis and outlook inside.
Vir Biotechnology (VIR) stock surges 60% on Astellas partnership worth $335M upfront, strong Phase 1 prostate cancer data, and Q4 earnings beat.